TY - JOUR
T1 - Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity
AU - Gali, Youssef
AU - Ariën, Kevin K.
AU - Praet, Marleen
AU - Van den Bergh, Rafael
AU - Temmerman, Marleen
AU - Delezay, Olivier
AU - Vanham, Guido
N1 - Funding Information:
Youssef Gali is a predoctoral fellow of the Institute for Science and Technology (IWT). This work was supported by the Research Foundation – Flanders (Belgium) (G.0125.06) and the Agence Nationale de Recherches sur le Sida [ANRS] . The authors are grateful to the Dormeur Foundation for supporting our research by funding our TriStar fluorometer and to the Antwerp Red Cross Blood Transfusion Center for providing buffy coats. The author thanks the EUROPRISE Network of Excellence for support.
PY - 2010/5
Y1 - 2010/5
N2 - Heterosexual transmission of human immunodeficiency virus (HIV-1) is the predominant mode of infection worldwide. However, the early steps of transepithelial infection still need to be clarified. Using epithelial cells, originating from the female genital tract, and peripheral blood mononuclear cells as subepithelial target cells, an in vitro dual-chamber model of the female genital tract was developed. Remarkably, an intact layer of some cell types (HEC-1A, CaSki and Ect1) served as a protective barrier against cell-free but not against cell-associated HIV-1 that crossed the epithelial barrier through transmigration. Furthermore, dysfunctions of the epithelial layers were assessed by monitoring transepithelial electric resistance and transepithelial passage of FluoSpheres® and HIV-1 after treatment with nonoxynol-9 (N-9). Most of the functional assays showed dysfunction of the epithelial barrier at lower concentrations compared to a widely used colorimetric toxicity assay (WST-1). Finally, N-9 treatment caused a significant increase in the production of interleukin-8 (IL-8) and macrophage inflammatory protein-3α (MIP-3α) and a decrease of Secretory Leukocyte Protease Inhibitor (SLPI) and Monocyte Chemotactic Protein-1 (MCP-1) in this model. In conclusion, this model is a useful tool to (1) study HIV-1 transmission mechanisms and (2) evaluate epithelial toxicity of candidate microbicides.
AB - Heterosexual transmission of human immunodeficiency virus (HIV-1) is the predominant mode of infection worldwide. However, the early steps of transepithelial infection still need to be clarified. Using epithelial cells, originating from the female genital tract, and peripheral blood mononuclear cells as subepithelial target cells, an in vitro dual-chamber model of the female genital tract was developed. Remarkably, an intact layer of some cell types (HEC-1A, CaSki and Ect1) served as a protective barrier against cell-free but not against cell-associated HIV-1 that crossed the epithelial barrier through transmigration. Furthermore, dysfunctions of the epithelial layers were assessed by monitoring transepithelial electric resistance and transepithelial passage of FluoSpheres® and HIV-1 after treatment with nonoxynol-9 (N-9). Most of the functional assays showed dysfunction of the epithelial barrier at lower concentrations compared to a widely used colorimetric toxicity assay (WST-1). Finally, N-9 treatment caused a significant increase in the production of interleukin-8 (IL-8) and macrophage inflammatory protein-3α (MIP-3α) and a decrease of Secretory Leukocyte Protease Inhibitor (SLPI) and Monocyte Chemotactic Protein-1 (MCP-1) in this model. In conclusion, this model is a useful tool to (1) study HIV-1 transmission mechanisms and (2) evaluate epithelial toxicity of candidate microbicides.
KW - Dual-chamber model
KW - Epithelial toxicity
KW - Female genital tract
KW - HIV-1 transmission
KW - Microbicides
KW - Transmigration
UR - http://www.scopus.com/inward/record.url?scp=77951022974&partnerID=8YFLogxK
U2 - 10.1016/j.jviromet.2010.01.018
DO - 10.1016/j.jviromet.2010.01.018
M3 - Article
C2 - 20138087
AN - SCOPUS:77951022974
SN - 0166-0934
VL - 165
SP - 186
EP - 197
JO - Journal of Virological Methods
JF - Journal of Virological Methods
IS - 2
ER -